On June 3, during ENDO 2024 in Boston, “Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline” was officially released. While this new guideline suggests supplements might benefit specific populations and questions the need for testing, it also suggests that more research is needed to determine optimal levels for specific health...
Guideline recommends vitamin D higher than the recommended daily allowance for children, pregnant people, adults over 75 and adults with prediabetes Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require testing for...
Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024 in Boston, Mass., and published in the journal Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Xerix Announces Results of Once-Weekly Subcutaneous Hypothyroidism Therapy On May 30, Xeris Biopharma Holdings, Inc., announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s...
What do podcasting, grant writing, microaggressions, and retirement all have in common? They are all topics covered by new Professional Development Workshops at ENDO 2024! When attendees descend on Boston in June for ENDO 2024, they will have the opportunity to participate in a series of workshops that will enhance their visibility in the endocrine...
Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...
Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...
In honor of National Asian American and Pacific Islander Heritage Month, Endocrine News reached out to several of our U.S.-based Asian members to get their thoughts on their careers, accomplishments, goals, and even their challenges, as well as advice they have for any young Asian American endocrinologists just beginning their careers. Since 2009, when President...
In honor of National Asian American and Pacific Islander Heritage Month, Endocrine News reached out to several of our U.S.-based Asian members to get their thoughts on their careers, accomplishments, goals, and even their challenges, as well as advice they have for any young Asian American endocrinologists just beginning their careers. Since 2009, when President...
